BCL2 and melanoma: Studies in melanoma have identified two Bcl-2 family proteins: proapoptotic Noxa and antiapoptotic Mcl-1 as the targets for bortezomib (Fernández et al. 2005; Wolter et al. 2007; Reuland et al. 2012; Selimovic et al. 2013).